{"organizations": [], "uuid": "c178d2cf2c01ddca6f157fba8f8da6419b243d08", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/11", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/pr-newswire-regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2018-financial-results-and-recent-operational-highlights.html", "country": "US", "domain_rank": 767, "title": "REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.073, "site_type": "news", "published": "2018-05-02T00:05:00.000+03:00", "replies_count": 0, "uuid": "c178d2cf2c01ddca6f157fba8f8da6419b243d08"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/pr-newswire-regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2018-financial-results-and-recent-operational-highlights.html", "ord_in_thread": 0, "title": "REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights", "locations": [], "entities": {"persons": [], "locations": [{"name": "md.", "sentiment": "none"}, {"name": "rockville", "sentiment": "none"}], "organizations": [{"name": "regenxbio inc.", "sentiment": "negative"}, {"name": "regenxbio inc", "sentiment": "none"}, {"name": "regenxbio", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ROCKVILLE, Md., May 1, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2018 and recent operational highlights.\nTo access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1862239. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com . The recorded webcast will be available for approximately 30 days following the call.\nAbout REGENXBIO Inc.\nREGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV ® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.\nCONTACT:\nInvestors\nNatalie Wildenradt, 646-681-8192\nnatalie@argotpartners.com\nMedia\nAdam Pawluk, 202-591-4063\napawluk@jpa.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2018-financial-results-and-recent-operational-highlights-300639475.html\nSOURCE REGENXBIO Inc.", "external_links": ["http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2018-financial-results-and-recent-operational-highlights-300639475.html", "http://www.regenxbio.com/"], "published": "2018-05-02T00:05:00.000+03:00", "crawled": "2018-05-02T02:27:46.032+03:00", "highlightTitle": ""}